Skip to main content

Milk Thistle

Scientific Name(s): Silybum marianum (L.) Gaertn.
Common Name(s): Carduus marianus, Fructus cardui mariae, Fructus silybi mariae, Mariana mariana, Blessed milk thistle, Bull thistle, Chardon de Marie, Holy thistle, Lady's milk, Lady's thistle, Marian thistle, Mary thistle, Mild marian thistle, Milk thistle, Pternix, Shui fei ji, Silberdistil, Silibinin, Silybe, Silybon, Silybum, Silymarin, St. Mary's thistle, Thistle, Thistle of the Blessed Virgin, Wild artichoke

Medically reviewed by Last updated on Mar 31, 2022.

Clinical Overview


Milk thistle has been investigated for its anti-inflammatory, antimicrobial, and CNS effects. It has been studied for use in allergic rhinitis, asthma, cancer treatment–related adverse effects, rheumatoid arthritis, type 2 diabetes, drug-induced hepatotoxicity, drug-induced nephrotoxicity, dyslipidemia, and thalassemia; however clinical trials supporting these uses are limited. Milk thistle is most commonly evaluated for use in the management of liver diseases (alcohol-induced and viral hepatitis) but the majority of clinical trials show equivocal results.


Milk thistle is considered safe in dosages of 420 mg/day orally in divided doses for up to 41 months. One source suggests daily doses of 12 to 15 g of dry fruits for dyspepsia and disorders of the biliary system, while an extract containing 200 to 400 mg/day of silymarin is considered effective in various liver disorders.


Milk thistle is contraindicated in patients with allergy to any plant in the Asteraceae family. Avoid use of the aboveground parts of the plant in women with hormone-sensitive conditions (eg, breast, uterine, and ovarian cancers; endometriosis; uterine fibroids) unless under the supervision of a physician, due to the extract's possible estrogenic effects. The more commonly used milk thistle seed extracts are not known to have estrogenic effects.


Milk thistle has traditionally been used in pregnancy. Limited clinical studies in pregnancy demonstrate use without apparent adverse effects; however, further data are needed to confirm safety. Caution should be used in pregnant and breastfeeding women.


There are mixed data regarding milk thistle's ability to exert inhibitory or inductive activity on cytochrome P450 (CYP-450) 1A2, 2C19, 2D6, 2E1, and 3A4, as well as P-glycoprotein. Therefore, close monitoring is warranted when drugs metabolized by these enzymes are given concomitantly with milk thistle.

Adverse Reactions

Silymarin is well tolerated; the most common adverse effects after oral ingestion were brief GI disturbances (eg, abdominal bloating, abdominal fullness or pain, anorexia, changes in bowel habits, diarrhea, dyspepsia, flatulence, nausea). Headache and pruritus have also been reported.


Toxic effects of silymarin have not been noted clinically at a dosage of 1,200 mg/day; however, mild allergies have been reported with dosages greater than 1,500 mg/day.

Scientific Family

  • Asteraceae (daisy)


Milk thistle is indigenous to Europe, Asia, and northern Africa, but has been naturalized in North and South America and Australia. The tall biennial plant grows 5 to 10 feet in height and has large, prickly leaves. The leaves have white markings or "milky veins." When broken, the leaves and stems exude a milky sap, from which the plant derives its name. The flowers are reddish-purple and ridged with sharp spines. The shiny, mottled, black- or grey-toned fruits, often referred to as "seeds," are used in making the extract. The fruits make up the thistle portion along with its silvery pappus, which readily falls away and is not used for the extract preparation.Mastron 2015, Neha 2016, NIH 2018, USDA 2018, WHO 2004


The name "milk thistle" comes from the story of the Virgin Mary who was sheltering under the thorny leaves of the milk thistle while nursing baby Jesus. A drop of Mary's milk fell, causing the distinctive white veins on the leaves of milk thistle.Chambers 2017, Mastron 2015 The fruit, stem, and seeds are considered to have medicinal value. Milk thistle has been used medicinally since the fourth century BC. Dioscorides (AD 40 to 90), a Greek physician and botanist, was the first to describe the healing properties of milk thistle.Siegel 2013 Its use in treating hepatobiliary diseases dates back to the 1700s, and its use as a liver protectant can be traced to Greek references. Pliny the Elder (AD 23 to 79) noted that the plant's juice was excellent for "carrying off bile." The ancient Greek and Romans used milk thistle for snake bites.Mastron 2015 The 17th century English herbalist Nicholas Culpepper described milk thistle as beneficial in treating jaundice and in removing liver and spleen obstructions. In the Eclectic medicine movement (19th to 20th century), milk thistle was used to treat varicose veins, menstrual difficulty, and congestion in the liver, spleen, and kidneys. In homeopathic medicine, a tincture of the seeds has been used to treat liver disorders, jaundice, gallstones, peritonitis, hemorrhage, bronchitis, and varicose veins.

Early colonists introduced milk thistle to North America. The plant was first grown in Europe and the de-spined leaves were used in salads and eaten as a vegetable; the stalks and root parts were also consumed. The flower portion was eaten "artichoke-style" and the roasted seeds were used as a coffee substitute.Neha 2016, Schauenberg 1990, WHO 2004, Xiong 2017


The active ingredient in milk thistle is silymarin. Silymarin is composed of 65% to 80% of a complex of flavonolignans: silybin A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, silydianin, and the flavonoid taxifoline. The remainder consists of fatty acids, betaine, apigenin, silybonol, proteins, fixed oil, and polyphenolic compounds. Silybin A and B, diastereoisomers of silibinin in a 1:1 ratio, are considered the most biologically active components. Milk thistle has poor oral availability, and as such, phospholipid complexes of silibinin and silymarin help improve absorption.Chambers 2017, Esmaeil 2017, Mastron 2015, Neha 2016, Stolf 2017

Uses and Pharmacology

Allergic rhinitis/Asthma

Milk thistle may be beneficial in allergic rhinitis by reducing mast cell anaphylaxis-like reactions and stabilizing the mast cell membrane.(Esmaeil 2017)

Animal and in vitro data

In a murine model, pretreatment with silibinin reduced airway hyper-responsiveness and inflammation.(Choi 2012)

Clinical data

In a study of 60 patients with allergic rhinitis and a positive allergy skin test, oral silymarin 140 mg 3 times a day for 1 month in addition to antihistamine therapy significantly improved clinical symptom severity, as measured by the SinoNasal Outcome Test 20 (SNOT-20), compared with control (9.23±5.14 vs 2.20±2.69; P<0.001). Patients treated with silymarin also had a higher posttreatment serum immunoglobulin E level, which could indicate an allergic reaction to silymarin, but this effect could not be confirmed.(Bakhshaee 2011)

Anticlastogenic activity

Animal and in vitro data

Silymarin has demonstrated strong anticlastogenic activity (ie, inhibition of damage to chromosomes) in murine somatic and germ cells.(Anwar 2018)

Antimicrobial effects

Animal and in vitro data

In an in vitro study, silibinin exerted activity against Escherichia coli but not Pseudomonas aeruginosa and Staphylococcus aureus. Both silibinin and silymarin exerted activity against Candida albicans, Candida tropicalis, and Candida krusei.(de Oliveira 2015) Additionally, silibinin demonstrated a membrane-damaging effect as well as antibiofilm activity on C. albicans.(Yun 2017) Dehydroisosilybin A, a component of milk thistle, demonstrated synergistic effects with amphotericin B against Leishmania.(Olías-Molero 2018) Another study found silybin may be an efflux pump inhibitor; the compound eliminated the plasmid from methicillin-resistant S. aureus (MRSA) 41577, restoring the bacteria's sensitivity to antibiotics. Further investigation is warranted.(Wang 2018) Silibinin inhibited HIV-1 replication in vitro.(McClure 2012)

Antiosteoporotic activity

Animal data

In ovariectomized rats, treatment for 12 weeks with silymarin prevented bone loss, either through increasing formation via an effect on calcium, phosphorus, osteocalcin, and parathyroid hormone, or through direct action with estrogen receptor-beta.(El-Shitany 2010) In another study of ovariectomized mice, silibinin or milk thistle extract 10 mg/kg/day administered for 8 weeks improved femoral bone mineral density and inhibited femoral bone loss caused by estrogen deficiency.(Kim 2013)


Silibinin may also induce autophagy, an evolving process of lysosomal proteolysis, which is vital for healthy organisms.(Pallauf 2013)


Animal and in vitro data

In vitro experiments and limited animal studies investigated the potential of silymarin and silibinin in a variety of cancer cell lines, including bladder, breast, cervical, colorectal, hepatocellular, gastric, lung, oral, ovarian, renal, and prostate. Several molecular mechanisms have been proposed, including antioxidant and anti-angiogenic actions, apoptosis via cell cycle arrest and modulation of proteins, inhibition of cell migration, inhibition of transcription factors, inhibition of proliferation, and modulation of hormone receptors and cell signaling.(Fan 2014, Imai-Sumida 2017, Ma 2015, Mastron 2015, Pirouzpanah 2015, Raina 2016, Singh 2016, Son 2015, Won 2018, Zhu 2016) Additionally, silibinin works synergistically with paclitaxel against gastric cancer cells through triggering cell cycle arrest and apoptosis.(Zhang 2018)

Clinical data

In a clinical trial of patients with prostate cancer and rising prostate-specific antigen (PSA) levels following radical prostatectomy or radiotherapy, a dietary supplement containing silymarin, soy, isoflavones, lycopene, and antioxidants delayed PSA progression; however, because the product contained several ingredients, outcomes cannot be attributed to any single ingredient.(Schröder 2005)

In another study, use of Legasil (a silibinin-based product) reduced peritumoral brain edema in 2 patients with brain metastases from lung cancer.(Bosch-Barrera 2016)

Use of milk thistle or its active components as adjunctive therapy to prevent chemotoxicities associated with chemotherapy and/or radiation has been studied. In one study in children with acute lymphoblastic leukemia (ALL), silibinin (as Siliphos) was administered for 28 days and compared to placebo. Those receiving silibinin achieved a greater reduction in total bilirubin at day 28 compared with placebo.(Greenlee 2007, NIH 2018),

In a randomized, double-blind, placebo-controlled study, effects of silymarin 140 mg 3 times daily on radiation-induced oral mucositis were assessed in 27 patients with head and neck cancer. At the end of the first to sixth week, median World Health Organization and National Cancer Institute Common Terminology Criteria scores were significantly reduced in the patients treated with silymarin (P<0.05). During radiation therapy, scores significantly increased in both the silymarin and placebo groups, but the silymarin group experienced a delay in the development and progression of oral mucositis.(Elyasi 2016)

The effect of silymarin on capecitabine-induced hand-foot syndrome was evaluated in 40 patients with GI cancer in a double-blind, randomized, placebo-controlled trial. Silymarin gel (1%) containing 80% active ingredient based on silymarin flavonolignans was applied twice daily to the soles and palms for the 9-week chemotherapy cycle. By week 9, development and progression of hand-foot syndrome were significantly lower in the silymarin group compared to placebo (P=0.03).(Elyasi 2017)

Cardiovascular disease

Clincal data

In 26 young healthy men, administration of a standardized milk thistle capsule (Legalon) at 140 mg given 3 times daily for 2 weeks did not affect circulating unconjugated bilirubin concentrations, which was in contrast to expectations as mild elevations were thought to offer cardiovascular risk benefit. Additionally, no changes were observed in lipid parameters (ie, total cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides), antioxidant capacity, or hs-CRP in a single-blind, randomized, placebo-controlled cross-over trial. No adverse events were reported.(Vidimce 2021)

CNS effects

Silymarin exerts antioxidant effects by inducing superoxide dismutase, increasing cellular glutathione content, and inhibiting lipid peroxidation.(Esmaeil 2017, Milić 2013) Silymarin is a direct free radical scavenger.(Surai 2015) It has been studied for its effects in CNS conditions such as Alzheimer and Parkinson disease.

Animal and in vitro data

In a murine model of Parkinson disease, pretreatment with silibinin improved motor disability, dopaminergic neuronal loss, and glial activation, as well as suppressed astroglial activation.(Lee 2015)

In a murine model of Alzheimer disease, silibinin exerted inhibitory activity against acetylcholinesterase and amyloid-beta aggregation.(Duan 2015)

Clinical data

A double-blind, randomized, comparator study in 35 patients with obsessive-compulsive disorder reported similar efficacy between 8-week treatment with milk thistle extract (600 mg/day [taken as 200 mg capsules 3 times a day]) and fluoxetine (30 mg/day [taken as 10 mg capsules 3 times a day]). No significant differences were observed between groups with regard to incidence of adverse effects or attrition rate.(Sayyah 2010) In 20 adults and children with compulsive hair pulling (trichotillomania), a significant effect was noted for milk thistle compared to placebo for some secondary endpoints (time spent per day pulling hair [P=0.039] and clinician-based severity scale [P=0.004]) but not the primary measure of severity. However, both the experimental and placebo groups experienced improvements in psychosocial functioning. This was a double-blind, randomized, controlled crossover in which milk thistle was initiated at 150 mg twice daily for 2 weeks then increased to 300 mg twice daily for the remaining 4 weeks.(Grant 2019) A 2021 Cochrane review of all published studies of pharmacotherapy for trichotillomania identified Grant 2019 (summarized above) as the only study that assessed silymarin and noted little to no difference between treatment groups.(Hoffman 2021)

Dermatological effects

Silybin and silymarin have been studied in the treatment of aging skin and rosacea, as well as in skin cancer prevention.(Berardesca 2008, Chambers 2017, Singh 2005, Singh 2009) S. marianum may be beneficial in slowing skin aging due to its ability to inhibit radicals. It also plays a role in ultraviolet (UV) B-tumor initiation and promotion.(Chambers 2017) Additionally, it has demonstrated antiglycation activity.(Shin 2015)


Milk thistle may be effective in the management of diabetes due to its effects on reducing glucose levels, increasing insulin sensitivity, and enhancing beta-cell regeneration.(Stolf 2017, Tajmohammadi 2018)

Animal and in vitro data

A review of in vitro and animal studies suggests that silybin (silibinin) acts as an aldose reductase inhibitor and can reduce glucose levels.(Kazazis 2014) Another study determined that isosilybin A, one of silymarin's constituents, exerted agonist activity on the peroxisome proliferator-activated receptor (PPAR)-gamma.(Pferschy-Wenzig 2014)

Silymarin reduced oxidative stress and inflammation in a murine model of streptozotocin-induced diabetes.(Stolf 2018) In another study of streptozotocin-induced diabetes in rats, 22 weeks of silybin administration prevented the development of obliterated retinal capillaries, suggesting a need for further research regarding a role in diabetic retinopathy.(Zhang 2014)

Clinical data

A small, triple-blind, randomized, placebo-controlled trial (N=40) documented statistically significant improvements in glycemic indices in adults with at least a 6-month history of type 2 diabetes. Serum glucose, insulin, insulin resistance, and insulin sensitivity were significantly improved after 45 days of silymarin extract 420 mg/day (range, P=0.001 to P=0.04) after adjusting for covariates (ie, baseline glycemic and anthropomorphic values, oral hypoglycemic and dyslipidemic agents, duration of disease, caloric intake, physical activity). Significant changes were also found in some, but not all, lipid parameters, with a negative correlation observed between insulin sensitivity and triglycerides (P=0.038) and a positive correlation noted between changes in insulin resistance and triglycerides (P=0.034). Treatment was well tolerated with no adverse events reported.(Ebrahimpour-Koujan 2018)

In a 2016 meta-analysis of 5 clinical trials in patients with type 2 diabetes (N=270), routine supplementation with silymarin reduced glucose levels (–26.86 mg/dL; 95% CI, –35.42 to –18.3) as well as hemoglobin A1c (–1.07%; 95% CI, –1.73% to –0.4%); however, no improvement in lipids was observed with silymarin.(Voroneanu 2016) Because milk thistle has demonstrated glucose-lowering effects, blood glucose should be carefully monitored when using milk thistle–containing products in patients with type 2 diabetes.

Drug-induced hepatotoxicity

Milk thistle has demonstrated efficacy in liver damage associated with acetaminophen, arsenic, and carbon tetrachloride.(Neha 2016)

Animal and in vitro data

In a study of rats, silibinin mitigated the increases in liver function measures caused by combination therapy with isoniazid and zidovudine.(Ramanathan 2017)

Clinical data

Prevention of anti-tuberculosis (TB) drug–induced liver injury was assessed in a double-blind, randomized, placebo-controlled trial in patients with newly diagnosed pulmonary tuberculosis (N=55) who planned to receive standard therapy with isoniazid, rifampicin, pyrazinamide, and ethambutol. Patients were randomly assigned to also receive silymarin 140 mg 3 times daily or placebo. Maximum ALT level within 4 weeks and development of anti-TB drug–induced liver injury were the primary and secondary outcome measures, respectively. Enrollment was terminated early due to slow accrual and safety reasons. Although the sample size was relatively small, administration of silymarin significantly reduced the incidence of anti-TB drug–induced liver injury at week 4 compared with placebo (3.7% vs 32.1%, respectively; P=0.012). However, median ALT levels were not significantly different between groups. Silymarin was well tolerated.(Luangchosiri 2015) The effect of silymarin on beta-interferon-induced hepatotoxicity was explored in a double-blind, randomized, placebo-controlled study (N=54). In patients with relapsing remitting multiple sclerosis undergoing beta-interferon therapy, adjunctive use of oral silymarin (420 mg/day) for 6 months led to significantly lower liver enzymes compared to placebo, specifically AST and ALT (P=0.002 and P=0.001, respectively). The overall disability scores were not significantly different between groups.(Abbasirad 2021)

In another similar study assessing the effects of silibinin on anti-TB drug–induced liver injury, different results were discovered. A group of 277 patients receiving conventional TB therapy and also given silibinin 70 mg 3 times daily for 8 weeks was compared with 291 patients receiving only conventional therapy for TB. At 2, 4, and 8 weeks, there were no differences between the 2 groups in the incidence of liver injury. Additionally, the number of patients diagnosed with drug-induced liver injury at 8 weeks was not different, nor was the percentage of patients with transient abnormal liver function tests. However, fewer cases of nausea and anorexia were reported in patients receiving silibinin compared with those who were not, and more patients in the silibinin group had negative smear cultures compared with those who did not receive silibinin.(Gu 2015) In a randomized controlled trial conducted in China (N=370), patients received anti-TB therapy with either supplemental S. marianum (200 mg twice daily) or vitamin C; no significant difference in the occurrence of probable or possible anti-TB drug–induced liver injury was observed between the 2 groups. Of the 215 patients who experienced an above normal AST/ALT ratio, a significantly higher abnormal ratio was observed in the S. marianum group (RR=1.29; 95% CI, 1.08 to 1.53; P=0.004). No significant differences in the prevention of adverse drug reactions or treatment duration and outcome were observed.(Zhang 2016)

Drug-induced nephrotoxicity

Animal and in vitro data

In a murine model, silybin protected against cisplatin-induced acute kidney injury through improving mitochondrial function via regulation of sirtuin 3 expression.(Li 2017)

Clinical data

In a pilot, randomized, double-blind, placebo-controlled clinical trial, hospitalized patients receiving cisplatin were administered placebo or oral silymarin 420 mg/day in 3 divided doses starting 1 to 2 days prior to cisplatin initiation and continuing through the end of 3 cycles of 21-day chemotherapy. Data from the 24 patients who completed the study reflected no difference between the intervention and control groups. Silymarin was well tolerated.(Shahbazi 2015)

In a study of patients with liver cirrhosis, silymarin did not exert protective effects against contrast-induced nephrotoxicity.(Kuo 2018)


Milk thistle is reported to possibly be effective in dyslipidemia due to a reduction in hydroxymethylglutaryl coenzyme A (HMG CoA) reductase as well as de novo synthesis in cholesterol.(Stolf 2017)

Animal and in vitro data

In a rat model of hereditary hypertriglyceridemia, 4 weeks of silymarin administration significantly reduced triglyceride and total cholesterol levels, and increased HDL cholesterol levels.(Poruba 2015)

Clinical data

In a triple-blind, randomized, placebo-controlled trial in adults with at least a 6-month history of type 2 diabetes (N=40), statistically significant improvements in some lipid parameters were observed in those receiving a standardized silymarin extract (490 mg/day for 45 days) compared to placebo. HDL (+4.57 mg/dL; P=0.035), triglycerides (−73.19 mg/dL; P=0.034), and triglyceride/HDL ratio (P<0.016) were significantly improved with silymarin compared with placebo; however, total cholesterol and LDL were not.(Ebrahimpour-Koujan 2018)

Immunomodulatory/Anti-inflammatory effects

Silymarin exerts anti-inflammatory effects through inhibition of nuclear factor kappa B and tumor necrosis factor alpha (TNF-alpha) activation. At low doses, silymarin inhibits T-lymphocyte function; however, high doses have been associated with activation of inflammation.(Esmaeil 2017) It also inhibits the migration of neutrophils to the site of inflammation.(Neha 2016)

In vitro data

In human liver and T cells, silymarin induced stress signaling and suppressed inflammation.(Lovelace 2015)

Clinical data

In a study of healthy men and women, silibinin reduced the expression of interleukin 17 (IL-17) and TNF-alpha, upregulated estrogen receptor-beta expression, induced apoptosis, and inhibited proliferation. In patients with active rheumatoid arthritis, the same effects on apoptosis, proliferation, and cytokine production were noted. Thus, silibinin may have a therapeutic role in states of inflammation such as rheumatoid arthritis.(Dupuis 2018)

Adding the silymarin supplement Livergol to standard rheumatoid arthritis drug therapy was reported to significantly improve various disease severity parameters. In a single-arm, non-randomized trial (n=44), 420 mg/day of silymarin given for 3 months improved joint tenderness, pain, swelling, erythrocyte sedimentation rate, C-reactive protein, and disease severity scores.(Shavandi 2017)

Liver diseases

Milk thistle is believed to exert its hepatoprotective effects through the promotion of hepatocyte growth and inhibition of oxidation and inflammation in the liver.(Ward 2013) Milk thistle may also increase protein synthesis in liver cells, a positive effect in degenerative liver diseases.(Awang 2009) Some reports suggest that oral silybin as a phytosome complex is better for the treatment of liver conditions.(Polachi 2016)

Animal and in vitro data

In a study of alcohol-induced inflammation of guinea pig hepatocytes, silymarin 25 mg per 100 g of body weight given for 30 days was associated with a reduction in liver function markers (ie, AST, ALT, gamma-glutamyltransferase [GGT]) compared with controls (alcohol abstention group). However, guinea pigs receiving ethanol plus ascorbic acid had a greater reduction in ALT and GGT compared with those receiving silymarin.(Abhilash 2013)

In a murine model of nonalcoholic steatohepatitis (NASH), treatment with silybin reduced hepatic steatosis, fibrosis, and inflammation through activation of nuclear factor erythroid 2-related 2 (Nrf2) pathway, suppression of nuclear factor kappa B signaling, and downregulation of inflammation-related gene expression.(Ou 2018) In another murine model of nonalcoholic fatty liver disease, S. marianum oil reduced lipid accumulation, oxidative stress, and inflammation, and improved the metabolism of lipids.(Zhu 2018)

Clinical data

A number of meta-analyses evaluating the efficacy of milk thistle in alcohol-induced and viral hepatitis have been conducted.(Liu 2003, Rambaldi 2005, Rambaldi 2007, Saller 2001, Saller 2008, Verma 2007) No effect on all-cause mortality was found, and no effect on complications of liver disease or on liver histology could be established.(Saller 2008) In a Cochrane review of 18 randomized clinical studies assessing use of milk thistle versus placebo or no intervention in patients with alcoholic or hepatitis B or C virus liver disease, milk thistle had no significant effects on mortality, complications of liver disease, or liver histology. Liver-related mortality was significantly reduced by milk thistle when all trials were assessed (relative risk [RR], 0.5; 95% CI, 0.29 to 0.88) but not in high-quality trials (RR, 0.57; 95% CI, 0.28 to 1.19).(Rambaldi 2007) In some trials, a reduction in serum transaminases was demonstrated but with no effect on liver histology or clinical progression.(Ferenci 2008, Mayer 2005, Saller 2008) Symptoms related to biliary retention resolved faster in 1 subsequent trial, but with no effect on quality-of-life measures.(El-Kamary 2009) One small, open-label study in viral hepatitis demonstrated a reduction in viral load with high-dose intravenous (IV) administration of silibinin.(Ferenci 2008) However, orally administered silymarin did not produce differences in serum hepatitis C virus titers, ALT, or quality-of-life measurements compared with placebo, according to a meta-analysis of 5 randomized clinical trials (N=389) published through April 2014.(Yang 2014) The Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial assessed the long-term use of silymarin in 1,049 patients with advanced fibrosis or cirrhosis after peginterferon and ribavirin therapy had failed. Use of silymarin was associated with less fibrosis as measured by the Ishak fibrosis score, but this association was not noted for clinical outcome measures.(Freedman 2011) The American Association for Study of Liver Disease (AASLD) practice guidelines for primary biliary cirrhosis (2009) and primary biliary cholangitis (2018) state that the addition of silymarin to ursodeoxycholic acid provided no additional benefit.(Lindor 2009, Lindor 2019)

A meta-analysis evaluated English and Chinese randomized placebo-controlled trials from 1966 to December 2011 to determine the safety and efficacy of silymarin as monotherapy and combination therapy for treatment of chronic hepatitis B.(Wei 2013) Data from 12 trials (N=1,096) suggest silymarin is equivalent to antiviral or hepatoprotective drugs with regard to effects on serum transaminases, viral load, and hepatic fibrosis markers. However, when silymarin was combined with these agents, serum indices and hepatic markers were reduced. Although the majority of studies were of poor quality, the positive synergistic effect is an important finding that can help inform future clinical studies.(Wei 2013)

In patients with hepatitis C, beneficial effects have not been noted with use of silymarin. In a multicenter, double-blind, placebo-controlled trial, 154 patients with chronic hepatitis C and elevated ALT levels who were unsuccessfully treated with interferon, silymarin 420 mg or 700 mg 3 times daily for 24 weeks did not significantly reduce ALT levels.(Fried 2012) In a study of children 5 to 16 years of age with nonalcoholic fatty liver disease, silymarin given for 12 weeks improved fatty liver infiltration, liver function tests, and triglyceride levels; however, LDL and HDL cholesterol levels were not altered.(Famouri 2017)

Milk thistle may be useful in acute hepatotoxicity due to amatoxin poisoning from ingestion of Amanita phallides or other Aminata mushrooms. Mechanisms include saturating receptor sites on liver cell membranes before the alpha-faloidine and alpha-amanitin toxins can bind and enter the cell.(Awang 2009, Milić 2013) Other potential mechanisms of action include competing with amatoxin for transmembrane transport, interrupting biliary secretion and thus enterohepatic recirculation of the toxin, inhibiting the release of TNF-alpha in damaged hepatocytes, and stimulating the synthesis of proteins in damaged liver cells.(Mengs 2012) A review of the literature found that use of IV silibinin (Legalon SIL) resulted in mortality rates of less than 10% in patients with amatoxin poisoning.(Mengs 2012)


Blood transfusions are the cornerstone of treatment for patients with thalassemia. In turn, patients can develop iron overload, leading to oxidative stress and organ damage.(Moayedi Esfahani 2015) Milk thistle has been suggested to be an iron chelator and has been evaluated in thalassemia for its ability to mitigate these effects.(Neha 2016)

Clinical data

A small trial (N=30) investigated the humoral and cell-mediated immunomodulatory effects of silymarin (140 mg 3 times daily) added to desferrioxamine therapy (40 mg/kg/day) for 12 weeks in patients 12 years and older with beta-thalassemia; 5 patients who were unable or unwilling to take desferrioxamine therapy received silymarin monotherapy. Neopterin, a marker of cellular immune system activation, and TNF-alpha were decreased in both groups after silymarin therapy, whereas production of interferon-gamma and IL-4 were increased. No adverse effect on frequency or function of immune cells was observed. These data indicate recovery of immune status and cytokine production.(Gharagozloo 2013)

The iron-chelating effects of silymarin were evaluated in a triple-blind, randomized, placebo-controlled crossover trial of patients with transfusion-dependent beta-thalassemia (N=82). Placebo or silymarin 420 mg/day (given in 3 divided doses) was administered orally as adjunctive therapy to a relatively stable iron chelation regimen for 12 weeks, with a 2-week washout between treatments. Data from the 69 patients who completed the trial reflected a significant treatment effect on median changes in some iron-chelating markers, with reductions in iron levels (P<0.001) and an improvement in total iron binding capacity (P=0.05). Liver iron concentration was also significantly reduced with administration of silymarin (P=0.02). Treatment was well tolerated with no reported adverse effects.(Darvishi-Kherzi 2018)

Varicocele-induced damage

Animal data

Silymarin 50 mg/kg/day for 42 days protected against varicocele-induced testicular atrophy in Wistar rats. Additionally, varicocelized rats receiving silymarin had higher testosterone levels and a larger percentage of sperm with nuclear maturity compared with varicocelized rats not receiving treatment.(Moshtaghion 2013)


Milk thistle is considered safe in dosages of 420 mg/day orally in divided doses for up to 41 months.Milić 2013, Tamayo 2007 One source suggests daily doses of 12 to 15 g of dry fruits for dyspepsia and disorders of the biliary system, while an extract containing 200 to 400 mg/day of silymarin is considered effective in various liver disorders.van Wyk 2004

A dose of 140 mg of silymarin 3 times daily has been suggested for hepatic cirrhosis.Stolf 2017

S. marianum leaf extract 600 mg/day (200 mg capsules 3 times daily) given for 8 weeks was as effective as fluoxetine in adults with obsessive-compulsive disorder in a small study.Sayyah 2010

A phase 1 clinical study in prostate cancer patients determined a phase 2 dosage recommendation of silibinin (as Siliphos) 13 g/day orally in 3 divided doses.Flaig 2007, Ramasamy 2008

A preparation consisting of 150 mL of boiling water poured over 3.5 g of crushed milk thistle seed, steeped for 10 to 15 minutes, and given 3 to 4 times daily 30 minutes before meals has been suggested for digestive disorders.Blumenthal 2003 Consumption of silymarin in the form of tea may not be effective, as silymarin is poorly soluble in water.Awang 2009

Pregnancy / Lactation

Milk thistle has traditionally been used in pregnancy. Limited clinical studies in pregnancy demonstrate use without apparent adverse effects; however, further data are needed to confirm safety.Deep 2007, Greenlee 2007 Caution should be used in pregnant and breastfeeding women.


In vitro and animal studies suggest potentially beneficial effects with milk thistle in pregnancy. In a study of rats receiving ethanol during specific weeks of the gestational period, coadministration of silymarin with ethanol resulted in no deficits in spatial working memory in rats on postnatal day 60, suggesting silymarin provided a protective effect against alcohol-induced learning issues.Neese 2004 In a study of peripheral blood mononuclear cells from preeclamptic women, silibinin inhibited nuclear factor kappa B activation and production of inflammatory cytokines.Giorgi 2012


Milk thistle may possess galactagogue effects by increasing prolactin levels.Dietz 2016 A study evaluated the efficacy and safety of silymarin to promote milk production in 50 women who had elected to stop breastfeeding because their infants did not consume the milk. Milk production was enhanced with no change to its chemical composition.Di Pierro 2008


There is mixed data regarding milk thistle's ability to exert inhibitory or inductive activity on CYP1A2, 2C19, 2D6, 2E1, and 3A4, as well as P-glycoprotein. Therefore, close monitoring is warranted when drugs metabolized by these enzymes are given concomitantly with milk thistle.(Asher 2017, Milić 2013, Polachi 2016, Sprouse 2016)

Deferiprone: UGT1A6 inhibitors may increase the serum concentration of deferiprone. Avoid combination.(Benoit-Biancamano 2009, Ferriprox July 2019, Ferriprox April 2018, Limenta 2008)

Fosphenytoin-Phenytoin: CYP2C9 inhibitors (weak) may increase the serum concentration of fosphenytoin-phenytoin. Monitor therapy.(Ahmad 1995, Ballek 1973, Blyden 1988, Brickell 2003, Christensen 1969, Dilantin October 2018, Gilbar 2001, Jensen 1985, Keerty 2021, Konishi 2002, Koup 1978, McGovern 1984, Nolan 1989, Nolan 1990, Ogutu 2002, Rose 1977, Rosemergy 2002, Shackleford 1987, Tsuda 2008, Vincent 1978, Wakisaka 1990)

Indinavir: Milk Thistle may decrease the serum concentration of indinavir. No action needed.(DiCenzo 2003, Jalloh 2017, Mills 2005, Piscitelli 2002)

Losartan: Milk thistle may decrease serum concentrations of the active metabolite(s) of losartan. Milk thistle may increase the serum concentration of losartan. No action needed.(Beckmann-Knopp 2000, Brantley 2010, Doehmer 2008, Han 2009, Jancova 2007, Sridar 2004)

Metronidazole (systemic): Milk thistle may decrease the serum concentration of metronidazole (systemic). No action needed.(Rajnarayana 2004)

Simeprevir: Concomitant use of simeprevir with milk thistle may result in increased plasma concentrations of simeprevir. Avoid combination.(Doehmer 2011, Olysio November 2017, Wu 2009)

Sirolimus products: Milk thistle may increase the serum concentration of sirolimus products. Monitor therapy. (DiCenzo 2003, Jiao 2009, Mills 2005, Piscitelli 2002)

Tolbutamide: CYP2C9 inhibitors (weak) may increase the serum concentration of tolbuamide. Monitor therapy.(Brunova 1977, Madsen 2001, Miners 1982, Orladeyo December 2020, Turalio October 2021, Wing 1985, Zahir 2021)

Vitamin K antagonists: CYP2C9 inhibitors (weak) may increase the serum concentration of vitamin K antagonists. Monitor therapy.(Accolate November 2013, Agrawal 2020, Hurtado 2021, Kumar 2011, Lash 2020, Leone 1999, Purkins 2003, Takahashi 1999, Woodward 2014, Xiao 2019, Yamamoto 2014)

Adverse Reactions

In most clinical trials, the incidence of adverse reactions was approximately equal in milk thistle and control groups.Zhu 2018 The US Agency for Healthcare Research and Quality and the German Commission E reported no serious adverse events associated with milk thistle within the recommended dosage range.Post-White 2007, Rainone 2005

Silymarin is well tolerated; the most common effects after oral ingestion were brief GI disturbances (eg, abdominal bloating, abdominal fullness or pain, anorexia, changes in bowel habits, diarrhea, dyspepsia, flatulence, nausea). Headache and pruritus have also been reported.Tamayo 2007 A tea made from crude milk thistle resulted in a case report of anaphylaxis.WHO 2004 High dosages in cancer trials have been associated with asymptomatic hyperbilirubinemia and increases in ALT enzymes.Tamayo 2007

A case report describes a 57-year-old woman with a 2-month history of intermittent episodes of sweating, nausea, colicky abdominal pain, diarrhea, vomiting, and weakness/collapsing. She recalled taking milk thistle for headaches and liver cleansing for about 2 months. Upon further questioning and cessation, it was determined that milk thistle was related to her symptoms.ADRAC 1999


Avoid use of the aboveground parts of the plant in women with hormone-sensitive conditions (eg, breast, uterine, and ovarian cancers; endometriosis; uterine fibroids), unless under the supervision of a physician, due to the extract's possible estrogenic effects. The more commonly used milk thistle seed extracts are not known to have estrogenic effects.Kidd 2005

Oral consumption of milk thistle (standardized to 70% to 80% silymarin) at 420 mg/day is considered safe for up to 41 months based on clinical trial data.Schandalik 1992 Acute oral toxicity of silymarin in rats, dogs, and monkeys has been estimated at dosages greater than 5 g/kg. Subacute toxicity studies suggest no toxicity in rats and monkeys at dosages up to 2 g/kg for 13 weeks, and up to 1 g/kg in rats and dogs for up to 26 weeks. Investigations, including urine analysis and postmortem studies, showed no evidence of toxicity. No evidence of effect on reproduction in rats has been found, and silymarin was not mutagenic in several tests.Plísková 2005, WHO 2004

Toxic effects of silymarin have not been noted clinically at a dosage of 1,200 mg/day; however, mild allergies were reported with dosages greater than 1,500 mg/day.Milić 2013



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Abbasirad F, Shaygannejad V, Hosseininasab F, et al. Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinicaltrial. Int Immunopharmacol. 2021;97:107715.33933848
Abhilash PA, Haikrishnan R, Indira M. Ascorbic acid is superior to silymarin in the recovery of ethanol-induced inflammatory reactions in hepatocytes of guinea pigs. J Physiol Biochem. 2013;69(4):785-798.23653339
Accolate (zafirlukast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2013.
Agrawal S, Heiss MS, Fenter RB, et al. Impact of CYP2C9-interaction drugs on warfarin pharmacogenomics. Clin Transl Sci. 2020;13(5):941-949.32270628
Ahmad S. Amiodarone and phenytoin: interaction. J Am Geriatr Soc. 1995;43(12):1449-1450.7490410
An adverse reaction to the herbal medication milk thistle (Silybum marianum). Adverse Drug Reactions Advisory Committee. Med J Aust. 1999;170(5):218-219.10092919
Anwar S, Madkor HR, Ahmed N, Wagih ME. In vivo anticlastogenic effect of silymarin from milk thistle Silybum marianum L. Indian J Pharmacol. 2018;50(3):108-115.30166747
Asher GN, Corbett AH, Hawke RL. Common herbal dietary supplement-drug interactions. Am Fam Physician. 2017;96(2):101-107.28762712
Awang DVC. Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals. 3rd ed. Boca Raton, FL: CRC Press; 2009:48-50.
Bakhshaee M, Jabbari F, Hoseini S, et al. Effect of silymarin in the treatment of allergic rhinitis. Otolaryngol Head Neck Surg. 2011;145(6):904-909.21952357
Ballek RE, Reidenberg MM, Orr L. Inhibition of diphenylhydantoin metabolism by chloramphenicol. Lancet. 1973;1(7795):150.4118490
Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol. 2000;86(6):250-256.10895987
Benoit-Biancamano MO, Connelly J, Villeneuve L, Caron P, Guillemette C. Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009;37(2):322-329.18971318
Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol. 2008;7(1):8-14.18254805
Blumenthal M. The ABC Clinical Guide to Herbs. New York, NY: Thieme New York; 2003:285-290.
Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol. 1988;28(3):240-245.3360972
Bosch-Barrera J, Sais E, Cañete N, et al. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget. 2016;7(22):32006-32014.26959886
Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther. 2010;332(3):1081-1087. doi: 10.1124/jpet.109.16192719934397
Brickell K, Porter D, Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer. 2003;89(4):615-616.12915866
Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K. Interaction of tolbutamide and chloramphenicol in diabetic patients. Int J Clin Pharmacol Biopharm. 1977;15(1):7-12.838527
Chambers CS, Holečkova V, Petrásková L, et al. The silymarin composition…and why does it matter??? Food Res Int. 2017;100(pt 3):339-353.28964357
Choi YH, Jin GY, Guo HS, et al. Silibinin attenuates allergic airway inflammation in mice. Biochem Biophys Res Commun. 2012;427(3):450-455.22842463
Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet. 1969;2(7635):1397-1399.4188280
Darvishi-Khezri H, Salehifar E, Kosaryan M, et al. Iron-chelating effect of silymarin in patients with β-thalassemia major: a crossover randomised control trial. Phytother Res. 2018;32(3):496-503.29235162
Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther. 2007;6(2):130-145.17548792
de Oliveira DR, Tintino SR, Braga MF. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. BioMed Res Int. 2015;2015:292797.2586677110.1155/2015/292797
DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003;23(7):866-870.12885100
Dietz BM, Hajirahimkhan A, Dunlap TL, Bolton JL. Botanicals and their bioactive phytochemicals for women's health. Pharmacol Rev. 2016;68(4):1026-1073.27677719
Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.
Di Pierro F, Callegari A, Carotenuto D, Tapia MM. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as a galactagogue. Acta Biomed. 2008;79(3):205-210.19260380
Doehmer J, Tewes B, Klein KU, Gritzko K, Muschick H, Mengs U. Assessment of drug-drug interaction for silymarin. Toxicol In Vitro. 2008;22(3):610-617.18249085
Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro. 2011:25(1);21-27.20828605
Duan S, Guan X, Lin R, et al. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease. Neurobiol Aging. 2015;36(5):1792-1807.25771396
Dupuis ML, Conti F, Maselli A, et al. The natural agonist of estrogen receptor β silibinin plays an immunosuppressive role representing a potential therapeutic tool in rheumatoid arthritis. Front Immunol. 2018;9:1903.30174672
Ebrahimpour-Koujan S, Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: a triple-blinded randomized controlled clinical trial. Phytomedicine. 2018;44:39-44.29895491
El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009;16(5):391-400.19303273
El-Shitany NA, Hegazy S, El-Desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Phytomedicine. 2010;17(2):116-125.19577454
Elyasi S, Hosseini S, Niazi Moghadam MR, Aledavood SA, Karimi G. Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2016;30(11):1879-1885.27555604
Elyasi S, Shojaee FSR, Allahyari A, Karimi G. Topical silymarin administration for prevention of capecitabine-induced hand-foot syndrome: a randomized, double-blinded, placebo-controlled clinical trial. Phytother Res. 2017;31(9):1323-1329.28635153
Esmaeil N, Anaraki SB, Gharagozloo M, Moayedi B. Silymarin impacts on immune system as an immunomodulator: one key for many locks. Int Immunopharmacol. 2017;50:194-201.28672215
Famouri F, Saleh MM, Rostampour N, Hashemi E, Shahsanaee A. The effect of silymarin on nonalcoholic fatty liver disease in children. J Herbmed Pharmacol. 2017;6:16-20.
Fan L, Ma Y, Liu Y, Zheng D, Huang G. Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells. Eur J Pharmacol. 2014;743:79-88.25242120
Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135(5):1561-1567.18771667
Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019.
Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.
Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007;25(2):139-146.17077998
Freedman ND, Curto TM, Morishima C, et al; HALT-C Trial Group. Silymarin use and liver disease progression in the Hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther. 2011;33(1):127-137.21083592
Fried MW, Navarro VJ, Afdhal N, et al; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012;308(3):274-282.22797645
Fructus Silybi Mariae. WHO Monographs on Selected Medicinal Plants. Vol 2. Geneva, Switzerland: World Health Organization; 2004:300-316.
Gharagozloo M, Karimi M, Amirghofran Z. Immunomodulatory effects of silymarin in patients with β-thalassemia major. Int Immunopharmacol. 2013;16(2):243-247.23624215
Gilbar PJ, Brodribb TR. Phenytoin and fluorouracil interaction. Ann Pharmacother. 2001;35(11):1367-1370.11724084
Giorgi VS, Peracoli MT, Peracoli JC, Witkin SS, Bannwart-Castro CF. Silibinin modulates the NF-ĸb pathway and pro-inflammatory cytokine production by mononuclear cells from preeclamptic women. J Reprod Immunol. 2012;95(1-2):67-72.22871551
Grant JE, Redden SA, Chamberlain SR. Milk thistle treatment for children and adults with trichotillomania. J Clin Psychopharmacol. 2019;39(2):129-134.30694881
Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther. 2007;6(2):158-165.17548794
Gu J, Tang SJ, Tan SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of silibinin in preventing drug-induced liver injury. Int J Clin Exp Med. 2015;8(3):4320-4327.26064348
Han Y, Guo D, Chen Y, Chen Y, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers Eur J Clin Pharmacol. 2009;65(6):585-591.19221727
Hoffman J, Williams T, Rothbart R, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021;9(9):CD007662.34582562
Hurtado FK, de Braud F, De Vastro Carpeno J, et al. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK positive advanced tumors [published online January 4, 2021]. Cancer Chemother Pharmacol. doi:10.1007/s00280-020-04180-333394101
Imai-Sumida M, Chiyomaru T, Majid S, et al. Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget. 2017;8(54):92032-92042.29190895
Jalloh MA, Gregory PJ, Hein D, Risoldi Cochrane Z, Rodriguez A. Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS. 2017;28(1):4-15.27655839
Jancova P, Anzenbacherova E, Papouskova B, et al,. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos. 2007;35(11):2035-2039. [PubMed 17670841]17670841
Jensen JC, Gugler R. Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther. 1985;37(4):407-410.3979002
Jiao Z, Shi XJ, Li ZD, Zhong MK. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br J Clin Pharmacol. 2009;68(1):47-60.19660003
Kazazis CE, Evangelopoulos AA, Kollas A, Vallianou NG. The therapeutic potential of milk thistle in diabetes. Rev Diabet Stud. 2014;11(2):167-174.25396404
Keerty D, Kessler R, Koverzhenko V, Peguero E. Dyskinesia during concomitant usage of phenytoin and capecitabine. Postgrad Med J. 2021;97:629.32769104
Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev. 2005;10(3):193-203.16164374
Kim JL, Kim YH, Kang MK, Gong JH, Han SJ, Kang YH. Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis. Biomed Res Int. 2013;2013:919374.23781510
Konishi H, Morita K, Minouchi T, Nakajima M, Matsuda M, Yamaji A. Probable metabolic interaction of doxifluridine with phenytoin. Ann Pharmacother. 2002;36(5):831-834.11978162
Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Colburn WA, Bruck E. Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther. 1978;24(5):571-575.699481
Kuo YJ, Chang HP, Chang YJ, Wu HH, Chen CH. Evaluation of nephroprotection of silymarin on contrast-induced nephropathy in liver cirrhosis patients: a population-based cohort study. Medicine (Baltimore). 2018;97(37):e12243.30212956
Kumar RM, Van Gompel JJ, Bower R, Rabinstein AA. Spontaneous intraventricular hemorrhage associated with prolonged diosmin therapy. Neurocrit Care. 2011;14(3):438-440.21400007
Lash DB, Ward S. CYP2C9-mediated warfarin and milk thistle interaction. J Clin Pharm Ther. 2019 Oct 21 [epub ahead of print].31633199
Lee T, Dugoua JJ. Nutritional supplements and their effect on glucose control. Adv Exp Med Biol. 2012;771:381-395.23393691
Lee Y, Chun HJ, Lee KM, Jung YS, Lee J. Silibinin suppresses astroglial activation in a mouse model of acute Parkinson's disease by modulating the ERK and JNK signaling pathways. Brain Res. 2015;1627:233-242.26434409
Leone R, Ghiotto E, Conforti A, Velo G. Potential interaction between warfarin and ocular chloramphenicol. Ann Pharmacother. 1999;33(1):114.9972397
Li Y, Ye Z, Lai W, et al. Activation of sirtuin 3 by silybin attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. Front Pharmacol. 2017;8:178.28424621
Limenta LM, Jirasomprasert T, Tankanitlert J, et al. UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol. 2008;65(6):908-916.18318774
Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50(1):291-308.19554543
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419.3007037510.1002/hep.30145
Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol. 2003;98(3):538-544.12650784
Lovelace ES, Wagoner J, MacDonald J, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling. J Nat Prod. 2015;78(8):1990-2000.26186142
Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015;15:334.26400476
Ma Z, Liu W, Zeng J, et al. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma. Oncol Rep. 2015;34(5):2461-2468.26323996
Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther. 2001;69(1):41-47.11180037
Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anticancer Drugs. 2015;26(5):475-486.25603021
Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12(6):559-567.16255756
McClure J, Lovelace ES, Elahi S, et al. Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation [published correction appears in PLoS One. 2012;7(10)]. PLoS One. 2012;7(7):e41832.22848626
McGovern B, Geer VR, LaRaia PJ, Garan H, Ruskin JN. Possible interaction between amiodarone and phenytoin. Ann Intern Med. 1984;101(5):650-651.6486598
Mengs U, Pohl RT, Mitchell T. Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol. 2012;13(10):1964-1970.22352731
Milić N, Milosević N, Suvajdzić L, Zarkov M, Abenavoli L. New therapeutic potentials of milk thistle (Silybum marianum). Nat Prod Commun. 2013;8(12):1801-1810.24555302
Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol. 2005;61(1):1-7.15666173
Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJ. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol. 1982;22(4):321-326.7106168
Moayedi Esfahani BA, Reisi N, Mirmoghtadaei M. Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review. Hemoglobin. 2015;39(2):75-80.25643967
Moshtaghion SM, Malekinejad H, Razi M, Shafie-Iranneja V. Silymarin protects from variocele-induced damages in testis and improves sperm quality: evidence for E2f1 involvement. Syst Biol Reprod Med. 2013;59(5):270-280.23659554
Neese S, La Grande L, Trujillo E, Romero D. The effects of ethanol and silymarin treatment during gestation on spatial working memory. BMC Complement Altern Med. 2004;4:4.15018621
Neha, Jaggi AS, Singh N. Silymarin and its role in chronic diseases. Adv Exp Med Biol. 2016;929:25-44.27771919
Milk Thistle. National Center for Complementary and Integrative Health. National Institutes of Health website. Updated September 2016. Accessed on October 28, 2018.
US National Institutes of Health. Silybum marianum. website. Accessed October 25, 2018.
Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther. 1989;46(1):43-50.2743707
Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. Am J Cardiol. 1990;65(18):1252-1257.2337037
Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Kokwaro GO. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol. 2002;54(6):635-642.12492612
Olías-Molero AI, Jiménez-Antón MD, Biedermann D, Corral MJ, Alunda JM. In-vitro activity of silybin and related flavonolignans against Leishmania infantum and L. donovani.Molecules. 2018;23(7).2995414510.3390/molecules23071560.
Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017.
Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020.
Ou Q, Weng Y, Wang S, et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the NF-ĸB pathway. Dig Dis Sci. 2018;63(12):3398-3408.3019149910.1007/s10620-018-5268-0
Pallauf K, Rimbach G. Autophagy, polyphenols and healthy ageing. Ageing Res Rev. 2013;12(1):237-252.22504405
Pferschy-Wenzig EM, Atanasov AG, Malainer C, et al. Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J Nat Prod. 2014;77(4):842-847.24597776
Pirouzpanah MB, Sabzichi M, Pirouzpanah S, Chavoshi H, Samadi N. Silibinin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways. Asian Pac J Cancer Prev. 2015;16(5):2087-2092.25773855
Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002;22(5):551-556.12013352
Plísková M, Vondrácek J, Kren V, et al. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology. 2005;215(1-2):80-89.16076518
Polachi N, Bai G, Li T, et al. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer – a comprehensive review. Eur J Med Chem. 2016;123:577-595.27517806
Poruba M, Kazdová L, Oliyarnyk O, et al. Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome. Xenobiotica. 2015;45(9):751-756.26068528
Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther. 2007;6(2):104-109.17548789
Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003;56(supp 1):24-29.14616410
Raina K, Kumar S,Dhar D, and Agarwal R. Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy. J Biomed Res. 2016;30(6):452-465.27476880
Rainone F. Milk thistle. Am Fam Physician. 2005;72(7):1285-1288.16225032
Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung. 2004;54(2):109-113.15038460
Ramanathan R, Sivanesan K. Evaluation of ameliorative ability of silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats: role of silibinin in phase I and II drug metabolism. Chem Biol Interact. 2017;273:142-153.28619387
Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269(2):352-362.18472213
Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005;100(11):2583-2591.16279916
Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;(4):CD003620.17943794
Rose JQ, Choi HK, Schentag JJ, Kinkel WR, Jusko WJ. Intoxication caused by interaction of chloramphenicol and phenytoin. JAMA. 1977;237(24):2630-2631.576989
Rosemergy I, Findlay M. Phenytoin toxicity as a result of 5-fluorouracil administration. N Z Med J. 2002;115(1159):U124.12362168
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-2063.11735632
Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008;15(1):9-20.18334810
Sayyah M, Boostani H, Pakseresht S, Malayeri A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):362-365.20035818
Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung. 1992;42(7):964-968.1329780
Schauenberg P, Paris F. Guide to Medicinal Plants. New Canaan, CT: Keats Publishing; 1990.
Schröder FH, Roobol MJ, Boevé ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005;48(6):922-930.16263208
Shackleford EJ, Watson FT. Amiodarone-phenytoin interaction. Drug Intell Clin Pharm. 1987;21(11):921.3678068
Shahbazi F, Sadighi S, Dashti-Khavidaki S, et al. Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, placebo-controlled clinical trial. Phytother Res. 2015;29(7):1046-1053.25857366
Shavandi M, Moini A, Shakiba Y, et al. Silymarin (Liergol®) decreases disease activity score in patients with rheumatoid arthritis: a non-randomized single-arm clinical trial. Iran J Allergy Asthma Immunol. 2017;16(2):99-106.28601049
Shin S, Lee JA, Kim M, Kum H, Jung E, Park D. Anti-glycation activities of phenolic constituents from Silybum marianum (milk thistle) flower in vitro and on human explants. Molecules. 2015;20(3):3549-3564.25706757
Siegel AB, Stebbing J. Milk thistle: early seeds of potential. Lancet Oncol. 2013;14(10):929-930.23993379
Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005;41(13):1969-1979.16084079
Singh RP, Agarwal R. Cosmeceuticals and silibinin. Clin Dermatol. 2009;27(5):479-484.19695480
Singh T, Prasad R, Katiyar SK. Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. Am J Cancer Res. 2016;6(6):1287-1301.27429844
Silybum marianum (L.) Gaerth. USDA, NRCS. 2018. The PLANTS Database (, 25 October 2018). National Plant Data Team, Greensboro, NC 27401-4901 USA.
Son Y, Lee HJ, Rho JK, et al. The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer. BMC Pulm Med. 2015;15:68.26143275
Sprouse AA, van Breeman RB. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab Dispos. 2016;44(2):162-171.26438626
Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004;32(6):587-594.15155549
Stolf AM, Cardoso CC, Acco A. Effects of silymarin on diabetes mellitus complications: A review. Phytother Res. 2017;31(3):366-374.28124457
Stolf AM, Campos Cardoso C, Morais H, et al. Effects of silymarin on angiogenesis and oxidative stress in streptozotocin-induced diabetes in mice. Biomed Pharmacother. 2018;108:232-243.30219681
Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel). 2015;4(1):204-247.26785346
Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silymarin marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Phytother Res. 2018;32(10):1933-1949.30015401
Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther. 1999;66(6):569-581.10613612
Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007;6(2):146-157.17548793
Tsuda A, Fujiyama J, Miki A, Hori S, Ohtani H, Sawada Y. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Cancer Chemother Pharmacol. 2008;62(3):427-432.18026730
Turalio (pexidartinib) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; October 2021.
van Wyk BE, Wink M, eds. Medicinal Plants of the World. Portland, OR: Timber Press; 2004:300.
Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol. 2007;5(4):408-416.17222587
Vidimce J, Pennell EN, Foo M, et al. Effect of silymarin treatment on circulating bilirubin and cardiovascular disease risk factors in healthy men: A single-blind, randomized crossover trial. Clin Pharmacol Drug Dev. 2021;10(10):1156-1165. doi:10.1002/cpdd.96234242497
Vincent FM, Mills L, Sullivan JK. Chloramphenicol-induced phenytoin intoxication. Ann Neurol. 1978;3(5):469.727733
Voroneanu L, Nistor I, Dumea R, Apeterii M, Covic A. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2016;2016: 5147468.27340676
Wakisaka S, Shimauchi M, Kaji Y, Nonaka A, Kinoshita K. Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi. 1990;81(4):192-196.2116374
Wang D, Xie K, Zou D, Meng M, Xie M. Inhibitory effects of silybin on the efflux pump of methicillin-resistant Staphylococcus aureus. Mol Med Rep. 2018;18(1):827-833.29845191
Ward J, Kapadia K, Brush E, Salhanick SD. Amatoxin poisoning: case reports and review of current therapies. J Emerg Med. 2013;44(1):116-121.22555054
Wei F, Liu SK, Liu XY, et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis. 2013;32(5):657-669.23247631
Wing LM, Miners JO. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.Br J Clin Pharmacol. 1985;20(5):482-485.3878154
Won DH, Kim LH, Jang B, et al. In vitro and in vivo anti-cancer activity of silymarin on oral cancer. Tumour Biol. 2018;40(5):1010428318776170.29764340
Woodward CJ, Deyo ZM, Donahue KE, Deal AM, Hawes EM. Clinically relevant interaction between warfarin and scuppernongs, a quercetin containing muscadine grape: continued questions surrounding flavonoid-induced warfarin interactions. BMJ Case Rep. 2014:bcr2013009608.24966255
Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol. 2009:121(2);185-193.19041708
Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65.30427584
Xiong F, Guan YS. Cautiously using natural medicine to treat liver problems. World J Gastroenterol. 2017;23(19):3388-3395.28596675
Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Biol Pharm Bull. 2014;37(12):1990-1993.25451849
Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects of tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:941085.25247194
Yun DG, Lee DG. Assessment of silibinin as a potential antifungal agent and investigation of its mechanism of action. IUBMB Life. 2017;69(8):631-637.28636236
Zahir H, Kobayashi F, Zamora C, et al. Evaluation of potential drug-drug interaction risk of pexidartinib with substrates of cytochrome P450 and p-glycoprotein. J Clin Pharmacol. 2021;61(3):298-306.32918831
Zhang HT, Shi K, Baskota A, Zhou FL, Chen YX, Tian HM. Silybin reduces obliterated retinal capillaries in experimental diabetic retinopathy in rats. Eur J Pharmacol. 2014;740:233-239.25066112
Zhang S, Pan H, Peng X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: a randomized controlled trial. J Gastroenterol Hepatol. 2016;31(2):409-416.26243373
Zhang Y, Ge Y, Ping X, Yu M, Lou D, Shi W. Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cells lines. Mol Med Rep. 2018;18(2):1835-1841.29901126
Zhu SY, Jiang N, Yang J, et al. Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice. Biomed Pharmacother. 2018;100:191-197.29428667
Zhu XX, Ding YH, Wu Y, Qian LY, Zou H, He Q. Silibinin: a potential old drug for cancer therapy [published online ahead of print July 18, 2016]. Expert Rev Clin Pharmacol.27362364

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.